Skip to content
Download PDF

Metabolomics

Chapter 502 | Part 20: Emerging Topics in Clinical Medicine · Parts 19-20 – Consultative & Emerging Topics · Chapter 502

Key Clinical Points

  1. Metabolomics measures metabolites (small molecules ≤1000 Da) to assess the metabolic state of a cell, tissue, or organism.
  2. The metabolome is downstream of the genome, epigenome, transcriptome, and proteome, closely reflecting clinical and experimental phenotypes.
  3. Untargeted metabolomics allows for broad discovery (relative quantification), while targeted metabolomics focuses on predefined subsets (absolute quantification).
  4. NMR-based methods are non-destructive and reproducible but have lower sensitivity; MS-based methods are highly sensitive but require complex, destructive sample preparation.
  5. Magnetic Resonance Spectroscopy (MRS) is used in vivo to measure metabolites like N-acetylaspartate (NAA) and choline for brain mass diagnosis.
  6. 2-hydroxyglutarate (2-HG) serves as a specific biomarker for IDH mutations in gliomas, aiding in diagnosis, prognosis, and therapy selection.
  7. Pharmacometabolomics aims to personalize drug dosing by linking baseline metabolomic profiles to pharmacokinetic (PK) and pharmacodynamic (PD) responses.
  8. Newborn screening programs utilize targeted LC-tandem MS to identify inborn errors of metabolism within the first few days of life.
  9. Sample handling (time, storage, diet, etc.) significantly impacts results; inconsistent handling can lead to false associations in large cohort studies.
  10. Mass Spectrometry Imaging (MSI) provides spatial information of metabolites in tissue sections, useful for identifying tumor margins and local drug concentrations.

DEFINITION & OVERVIEW

• Metabolites: Small molecules with a molecular mass of ≤1000 Da involved in biochemical processes to create macromolecules and meet energy needs. • Metabolome: - Definition: All metabolites in a given biological sample at a given time. - Omics Hierarchy: The metabolome is downstream of the genome, epigenome, transcriptome, and proteome → it reflects clinical and experimental phenotypes more closely. - Dynamics: Metabolite levels can change rapidly; they are sensitive to both upstream and downstream perturbations in metabolic pathways. This makes them useful for assessing both acute and chronic changes.

EPIDEMIOLOGY

• Cohort Studies: Used in large prospective studies for common, multifactorial diseases (e.g., diabetes, cardiovascular disease, and various cancers). • Newborn Screening: Utilized to identify inborn errors of metabolism within the first few days of life for early intervention.

ETIOLOGY & PATHOPHYSIOLOGY

• Sensitivity: High sensitivity to both acute and chronic changes due to rapid fluctuations in metabolite levels. • Confounding Factors: - Age: Impacts antioxidant/redox pathways and macromolecule breakdown products. - Sex: Influences steroid and lipid metabolism. - Diet & Fasting: Fasting impacts nearly all measured metabolite categories. - Sample Handling: Variations in time, storage, and geographic distribution can lead to false positives in large cohort studies.

CLINICAL FEATURES

• Standard Assays: Measurement of well-established metabolites like glucose, lactate, and ammonia. • Metabolic Signatures: Identification of clusters of metabolites (e.g., amino acids) associated with conditions like diabetes or pancreatic cancer. • Sepsis/Shock: Correlation of blood lactate with clinical tools such as APACHE II or SOFA; identification of modified amino acids linked to mitochondrial dysfunction. • Brain Masses & MRS Findings: - N-acetylaspartate (NAA): Abundant in neurons; loss indicates absence of neurons. - Choline: Correlates with cellularity and/or proliferation. - Choline/NAA Ratio: - \uparrow Ratio + Loss of NAA → Cancer. - Isolated \downarrow NAA (with stable or \downarrow Choline) → Brain abscess. - Lactate: Indicates tumor metabolism or acute hypoxic brain injury after stroke. - Glutamine/Glutamate: High levels indicate hyperammonemia (glutamate acts as a CNS sink for ammonia).

DIFFERENTIAL DIAGNOSIS

• Brain Masses: Differentiation between cancer and abscess based on the Choline to NAA ratio. • Inborn Errors of Metabolism: Identified by abnormal levels of specific metabolites or sets of metabolites. • Secondary Metabolic Defects: Identification of noncirrhotic hyperammonemia caused by catabolic stress (e.g., sepsis) in patients with subclinical or acquired urea-cycle defects.

INVESTIGATIONS & DIAGNOSIS

  1. Untargeted vs Targeted Metabolomics:
  2. Untargeted: Used for discovery; provides a broad overview but requires further investigation to assign signals to specific metabolites.
  3. Targeted: Focuses on predefined subsets; allows for absolute quantification of specific molecules of interest.
  4. Note: No single metabolomics technique is comprehensive; if a metabolite is not measured, its absence cannot be assumed (unlike genomics/transcriptomics).
  5. Technology Comparison (NMR vs MS):
  6. NMR-based:
  7. Pros: Non-destructive, reproducible, minimal sample preparation, inherently quantitative.
  8. Cons: Lower sensitivity (\sim50–200 metabolites at >1 μM).
  9. MS-based:
  10. Pros: High sensitivity (can distinguish >1000 metabolites at 10^{-2} to 10^{-3} μM lower than NMR).
  11. Cons: Destructive, requires complex sample preparation and standards.
  12. Table 502-1 Summary:
  13. Reproducibility: NMR (High) eq MS (Lower)
  14. Selectivity: NMR (Untargeted) eq MS (Targeted \gg untargeted)
  15. Sample Prep: NMR (Minimal) eq MS (Multiple preps)
  16. Quantitation: NMR (Inherently quantitative) eq MS (Complex; requires standards)
  17. Analytical Workflow (Chromatography & Mass Spectrometry):
  18. Step 1: Extraction → isolate metabolites from biological sample (destructive).
  19. Step 2: Derivatization → optional chemical modification to improve stability/detection.
  20. Step 3: Chromatography → physical separation based on chemical properties.
  21. Step 4: Mass Spectrometry → identification via mass-to-charge ratio (m/z).
  22. Magnetic Resonance Spectroscopy (MRS):
  23. In vivo measurement of lipids, sugars, and amino acids in specific volumes.
  24. Brain Masses:
  25. NAA: Abundant in neurons; loss indicates absence of neurons.
  26. Choline: Correlates with cellularity/proliferation.
  27. Ratio Analysis: \uparrow Choline/NAA + Loss of NAA → Cancer; Isolated \downarrow NAA → Abscess.
  28. Lactate: Indicates tumor metabolism or acute hypoxic injury (e.g., post-stroke).
  29. Glutamine/Glutamate: High levels indicate hyperammonemia.
  30. Mass Spectrometry Imaging (MSI):
  31. Provides spatial information of metabolites in tissue sections.
  32. Allows mapping of specific molecules to identify tumor margins or local drug concentrations.

MANAGEMENT & TREATMENT

  1. Pharmacometabolomics:
  2. Step 1: Obtain baseline metabolomic profile.
  3. Step 2: Link profile to pharmacokinetic (PK) and pharmacodynamic (PD) responses.
  4. Step 3: Use data to personalize drug dosing.
  5. Drug Monitoring and Toxicology:
  6. Use of targeted LC-tandem MS to detect specific drug metabolites (e.g., opioids).
  7. Advantage: Higher sensitivity than first-generation immunoassays; faster turnaround time.
  8. Newborn Screening:
  9. Target LC-tandem MS → identify inborn errors of metabolism within days of life.
  10. Targeted Therapy Selection (Gliomas):
  11. Detection of 2-hydroxyglutarate (2-HG) via MRS or LC-MS → identifies IDH-mutant subset → determines eligibility for targeted therapies.

SPECIAL CONSIDERATIONS

• Newborns and Children: Targeted screening for inborn errors of metabolism. • Sample Handling & Processing: Critical for large cohort studies; must control for time, storage, and geography to avoid false associations between metabolites and disease risk.

KEY PEARLS & CLINICAL TRAPS

• Metabolome Position: The metabolome is the closest 'omics' layer to the actual clinical phenotype. • NMR vs. MS: NMR is preferred for reproducibility and non-destructive analysis; MS is required for high sensitivity and identifying a larger number of metabolites. • 2-HG Significance: A specific biomarker for IDH mutations in gliomas; its presence is critical for diagnosis, prognosis, and therapy selection. • Choline/NAA Ratio: Essential for differentiating brain tumors from abscesses.

Reference Tables

TABLE 502-1 Comparison of Nuclear Magnetic Resonance (NMR)- Based and Mass Spectrometry (MS)-Based Approaches to…

Harrison's 22e, p.3976

FEATURE NMR MS
Reproducibility High Lower
Low (low μM)
Selectivity Untargeted Targeted >> untargeted
Minimal
Sample measurement Simple: single prep Multiple preps
50–200
Identification Easy, using one- or two-
dimensional databases		 Complex; need standards
and additional analyses
Inherently quantitative;
intensity proportional to
concentration
Sample recovery Easy, nondestructive No
Yes